The dopamine D2 receptor (DRD2) is a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system, particularly in the striatum, cortex, and limbic regions. It plays a critical role in regulating dopamine-mediated signaling pathways involved in motor control, reward processing, cognition, and emotion. DRD2 exists in two major isoforms (D2S and D2L) generated by alternative splicing, differing in the length of the third intracellular loop. Dysregulation of DRD2 has been implicated in neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia, addiction, and depression.
DRD2 antibodies are essential tools for studying the receptor's expression, localization, and function in both normal and pathological contexts. These antibodies are typically designed to target specific epitopes, such as extracellular domains or intracellular loops, and are validated for applications like Western blotting, immunohistochemistry, flow cytometry, and immunofluorescence. Selective DRD2 antibodies help distinguish between DRD2 and other dopamine receptor subtypes (e.g., DRD1. DRD3) and between the D2S and D2L isoforms.
Commercial DRD2 antibodies are often raised in rabbits or mice using peptide immunogens corresponding to conserved or isoform-specific regions. Their specificity is confirmed using knockout controls or siRNA-mediated knockdown. Research using these antibodies has advanced understanding of DRD2’s role in synaptic plasticity, antipsychotic drug mechanisms, and dopamine-related circuitry. However, variability in antibody performance across studies underscores the need for rigorous validation to ensure reproducibility.